Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature. Issue 3 (4th January 2018)

• Record Type: Journal Article
• Authors: Morgado‐Carrasco, Daniel; Fustà‐Novell, Xavier; Podlipnik, Sebastian; Combalia, Andrea; Aguilera, Paula
• Is Part Of: Photodermatology, photoimmunology & photomedicine. Volume 34:Issue 3(2018)
• Page Start: 194
• Page End: 199
• Publication Date: 2018-01-04
• Subjects: chronic inducible urticaria -- omalizumab -- photobiology -- physical urticaria -- solar urticaria -- urticaria; Photosensitivity disorders -- Periodicals; Dermatology -- Periodicals; Immunology -- Periodicals; 616.5
• DOI: 10.1111/phpp.12370
• Languages: English
• ISSNs: 0905-4383

Abstract

Summary: Background: Solar urticaria (SU) is a rare photodermatosis. Treatment is challenging, and outcomes are often disappointing. Omalizumab is an anti‐IgE, currently approved for treatment of chronic spontaneous urticaria. We sought to evaluate therapy with omalizumab in refractory SU and describe predictive factors for response. Materials/methods: Patients with refractory SU under treatment with omalizumab were included in this study. Clinical outcome was evaluated using the Urticaria Activity Score 7 (UAS7), Dermatology Life Quality Index (DLQI) and Pruritus Visual Analogue Scale (VAS). Complete clinical response (CCR) was defined as having an UAS7 = 0, DLQI <6 and VAS = 0. Phototesting was performed and compared to baseline. We performed a PubMed search to identify reported cases of SU in adults treated with omalizumab, analysing their characteristics in order to predict response to omalizumab. Results: Eight patients were included. Median age was 45.5 years (range, 23‐64). Light spectrum most commonly implicated was UV‐A. Clinical outcomes: 89% (7/8) achieved CCR with omalizumab. Phototesting was normal in 42.8% (3/7) of them. In our review, we identified 38 patients (including the current case series), and 68.4% showed favourable outcomes with omalizumab. Median time since onset of SU was lower in responders. Conclusions: Omalizumab can be an effective treatment in refractory SU.